AlphAIAlphAI — Financial news for AI agents
investing.comOCT 161 min read$IRWD

Ironwood names Tammi Gaskins CEO, McCourt to retire

Ironwood Pharmaceuticals (NASDAQ:IRWD) named Tammi Gaskins as CEO, effective January 1, 2027. Current CEO Tom McCourt will retire but remain on the board. Gaskins, who joined in 2020, led commercial efforts for LINZESS and apraglutide. McCourt led the acquisition of VectivBio, adding apraglutide to the pipeline.

Original reporting
investing.com
Published Oct 16, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 11:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IRWD
Neutral
high confidence
Mentioned
$IRWD
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IRWDNeutralMed
01

Why it matters

The CEO change is a primary corporate event that could influence stock valuation and investor sentiment.

02

Market read

Executive transition at Ironwood may cause short-term price movement; long-term impact depends on execution of pipeline.

03

What to watch

Gaskins' commercial success with LINZESS and apraglutide pipeline may mitigate concerns.

Relevance 7/10Novelty 7/10Timing: effective Jan 1, 2027; announcement today

Background

Ironwood is a biotech focused on gastrointestinal and rare diseases, with products like LINZESS and pipeline candidate apraglutide.

Company-level read

Ticker impact

$IRWDNeutralHigh confidence
Context

Ironwood Pharmaceuticals announced Tammi Gaskins will become CEO on Jan 1, 2027, replacing retiring CEO Tom McCourt.

Expected impact

likely modest downside as investors reassess management outlook

Evidence & confidence

CEO changes are material but the new CEO is an internal promotion with known track record, limiting upside potential.

Market effects

Sector

May affect biotech sector sentiment regarding leadership stability.

Regional

Limited to US-listed biotech investors.

Global

Low; impact confined to Ironwood and its peers.

Counterpoint

What could challenge this read

The internal promotion could be seen as a positive continuity signal, supporting upside.

Key entities

  • person
    Tammi Gaskins

    New CEO, previously Chief Commercial Officer.

  • person
    Tom McCourt

    Outgoing CEO, retiring from the role.

Read at source← All news

StoryIronwood Pharmaceuticals appoints Tammi Gaskins as CEO, Tom McCourt to retire

Also covered by

1 outlet

Related articles

AUG 13
$IRWDMedAI 9/10

Ironwood (IRWD) Q2 2026 Earnings Call Transcript

Ironwood Pharmaceuticals (IRWD) reported Q2 2026 results on an earnings call. LINZESS U.S. net sales were $282.3M, up 14% YoY, and full-year guidance was raised to $1.15B-$1.20B. Total revenue was $113.0M, adjusted EBITDA $83.0M, and GAAP net income $51.3M. The company also discussed STARS-2 and balance sheet actions, including $200M convertible note repayment.

fool.com6 min
AUG 6
$IRWDHigh

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

IRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results – Raises full-year 2026 LINZESS ® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase

SEC EDGAR 8-K4 min
JUL 14
$IRWDMed

Ironwood Appoints Dr. Jeffrey Silber As Chief Medical Officer; STARS-2 Trial Actively Recruiting

Ironwood Pharmaceuticals (IRWD) appointed Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, effective July 20, 2026, replacing retiring Dr. Michael Shetzline, who will advise during transition. IRWD said its confirmatory Phase 3 STARS-2 trial of apraglutide for SBS-IF began in June and is actively recruiting. IRWD shares last traded at $4.08, down 3.09%.

rttnews.com3 min
OCT 16
$HTHIYMed

Hitachi Energy Plans C$479 Mln North American Manufacturing Expansion

Hitachi Energy, a Hitachi subsidiary, plans to invest C$479 million in a new transformer insulation factory in Ontario, Canada. The Canadian government and Ontario province will contribute C$50 million total. The facility, set to open by 2028, will include Canada's first pressboard manufacturing line. Hitachi's stock closed at $35.74, down 1.24%.

rttnews.com2 min